Behavioral Studies Supporting Rx-to-OTC Switches Saul Shiffman, Ph.D. Professor, Psychology, Psychiatry & Pharmaceutical Sciences, University of Pittsburgh.

Slides:



Advertisements
Similar presentations
Nursing Diagnosis: Definition
Advertisements

PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Introduction to the User’s Guide for Developing a Protocol for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research.
Some comments on the 3 papers Robert T. O’Neill Ph.D.
CORE COMPETENCIES IN CLINICAL & TRANSLATIONAL RESEARCH: The Child Health Perspective I. Clinical & Translational Research Questions: Extract information.
Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.
Evaluating Discipline-based Goals and Educational Outcomes in Developmental Psychology Anne L. Law Department of Psychology Rider University.
Meta-analysis & psychotherapy outcome research
THE ETHICAL CONDUCT OF RESEARCH Chapter 4. HISTORY OF ETHICAL PROTECTIONS The Nuremberg Code The Office for Human Research Protections (OHRP), United.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Critical Appraisal of an Article by Dr. I. Selvaraj B. SC. ,M. B. B. S
…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.
Kansas Tobacco-Related Data Resources and Performance Measures Harlen Hays, MPH Office of Health Promotion, KDHE.
Chapter 17 Nursing Diagnosis
BC Jung A Brief Introduction to Epidemiology - XI (Epidemiologic Research Designs: Experimental/Interventional Studies) Betty C. Jung, RN, MPH, CHES.
Introducing small-group workshops as formative assessment in large first year psychology modules Suzanne Guerin School of Psychology, University College.
FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.
Committee Questions Design, Statistical Considerations and Study Conduct 1. There are no clear guidelines regarding the number of people that should be.
Study Designs Afshin Ostovar Bushehr University of Medical Sciences Bushehr, /4/20151.
Use of Community Based Participatory Research (CBPR) to Develop Nutrition Programs for Chronic Disease Prevention Elena Carbone, Dr.P.H., R.D., L.D.N.
Quality Through the Eyes of the Patient: State-of-the-Art Concepts Paul D. Cleary, Ph.D. April 10, 2001 Quality Through the Eyes of the Patient: State-of-the-Art.
1 Non-Sedating Antihistamines Rx-to-OTC Switch NDAC & PADAC Joint Meeting May 11, 2001 François Nader, MD Senior Vice-President Medical & Regulatory Affairs,
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Agresti/Franklin Statistics, 1 of 56  Section 4.3 What Are Good Ways and Poor Ways to Experiment?
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
SS440 Seminar: Unit 4 Research in Psychopathology Dr. Angie Whalen Kaplan University 1.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
Industry Recommendations on Evaluating OTC Consumer Behavior Douglas Ws. Bierer, Ph.D. Consumer Healthcare Products Association.
June 2003George Mason University1 Needs Assessment Farrokh Alemi, Ph.D.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Research Methods in Psychology Chapter 2. The Research ProcessPsychological MeasurementEthical Issues in Human and Animal ResearchBecoming a Critical.
1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,
Perspectives on Enhancing Consumer Outcomes with Topical Antifungals
Unit 5 HS Adrienne Palmer, BSPH, MHA, FACHE.
CHAPTER 2 Research Methods in Industrial/Organizational Psychology
Understanding your Community Needs and Resource Assessments Primary Prevention Institute 2015.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Bayesian Statistics & Innovative Trial Design April 3, 2006 Jane Perlmutter
Prilosec1 ® 20 mg Tablets Rx to OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products (HFD-560) Food and Drug Administration 1.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
Evaluating Consumer Comprehension of Prescription Drug Information Saul Shiffman, Ph.D. Senior Scientific Advisor, Pinney Associates Consulting to industry.
© 2006 Concentrics Research LLC Switch Challenges and Suggested Solutions Julie L. Aker President & CEO Concentrics Research.
1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.
Research Methods in Psychology Introduction to Psychology.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Improving the agenda for Advertising and Switching for Nonprescription products Advancing Self-Care and Responsible Self-Medication for a Healthier Future.
ISSUES & CHALLENGES Adaptation, translation, and global application DiClemente, Crosby, & Kegler, 2009.
Copyright © 2008 Delmar. All rights reserved. Chapter 4 Epidemiology and Public Health Nursing.
CLINICAL TRIALS.
ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.
Critically Appraising a Medical Journal Article
Presented by Rob Hemmings
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Clinical Trials Medical Interventions
Randomized Trials: A Brief Overview
CHAPTER 2 Research Methods in Industrial/Organizational Psychology
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Positive Impacts of Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials* SPECIFIC BENEFITS   SHORT-TERM MEDIUM-TERM LONG-TERM.
Clinical Trials.
Nursing Process in Pharmacology
Issues in Hypothesis Testing in the Context of Extrapolation
A Time for Change for Managing Patients With VTE Who Have Cancer
Patient Involvement in the Development and Use of Safe Medicines Introductory Section – Concepts to Consider CIOMS XI WG Second Meeting October 23-24,
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Behavioral Studies Supporting Rx-to-OTC Switches Saul Shiffman, Ph.D. Professor, Psychology, Psychiatry & Pharmaceutical Sciences, University of Pittsburgh Senior Scientific Advisor, Pinney Associates Partner, JSR LLC Chief Science Officer, invivodata, inc.

NDAC 9/25/062 Agenda  Predict/evaluate consumer behavior in the OTC environment  Consider more information on likely OTC use  Leverage a wider array of influences on OTC use  Expand scientific foundations of OTC switch

NDAC 9/25/063 The New OTC Paradigm  OTC switches increasingly complex  From acute treatment of symptomatic conditions to  Support of preventive lifestyle changes  Chronic treatment of asymptomatic conditions  Challenges ahead

NDAC 9/25/064 Behavioral End-Points in OTC Switch  Drug pharmacology typically well-understood  Considered safe & effective if used properly  Questions in OTC switch are behavioral  Critical question: Will consumer behavior lead to safe and effective use?

NDAC 9/25/065 Key Elements of OTC Simulation in Actual Use Studies  No learned intermediary  Sample consumers with interest in treatment  Consumer makes decisions regarding drug purchase / use / repurchase / discontinuation  Data-gathering may cause “reactivity”

NDAC 9/25/066 Strategies to Limit Reactivity: Reactivity vs. Insight StrategyProsCons Limit frequency of data collection contacts Reduce potential influence Reduce detail in data Maximize use of recall

NDAC 9/25/067 Strategies to Limit Reactivity: Reactivity vs. Insight StrategyProsCons Limit frequency of data collection contacts Reduce potential influence Reduce detail in data Maximize use of recall Ask very open questionsReduce information to subjects Reduce detail in data Introduce ambiguity

NDAC 9/25/068 Strategies to Limit Reactivity: Reactivity vs. Insight StrategyProsCons Limit frequency of data collection contacts Reduce potential influence Reduce detail in data Maximize use of recall Ask very open questionsReduce information to subjects Reduce detail in data Introduce ambiguity Conduct Self-selection tests separate from AUS Allow detailed debriefing of self- selection, without contaminating AUS Additional research burden Do not observe purchase

NDAC 9/25/069 Evaluating Study Outcomes: Focus on What’s Critical to Risk / Benefit  Focus on issues that matter most for consumer health  Identify and agree on core issues for particular switch  Design: Study & end-points to address key questions  Evaluation: Focus on key end-points for risk

NDAC 9/25/0610 Total Compliance Measures Highly Sensitive to Number of Warnings + Directions

NDAC 9/25/0611 Total Compliance Measures Highly Sensitive to Number of Warnings + Directions

NDAC 9/25/0612 Interpreting Outcomes: How Good is Good Enough?  No single standard; weigh by risk  Benchmarks:  Compliance with warnings in other domains  Behavior under Rx

NDAC 9/25/0613 Realistic Expectations of Warning Compliance  Experimental example: Warning to wear gloves/mask  Randomized to:  Range of different warnings  Cluttered vs. uncluttered setting  Evaluate compliance Wogalter et al (1993)

NDAC 9/25/0614 Compliance with Warning/Direction for Chemical Protection Wogalter et al (1993) +

NDAC 9/25/0615 Compliance with Warning/Direction for Chemical Protection Wogalter et al (1993) ++

NDAC 9/25/0616 Compliance with Warning/Direction for Chemical Protection Wogalter et al (1993) +++

NDAC 9/25/0617 Context for OTC Switch: Rx Use Patterns  Evaluate change: existing Rx context vs. OTC  Real-world Rx use as benchmark  Example: OTC Switch of Nicotine Replacement Therapy (NRT): Nicotine gum and patch

NDAC 9/25/0618 Prescribing Practices for NRT (Pre-OTC Switch, Patient Reports) Shiffman et al (in press)

NDAC 9/25/0619 Prescribing Practices for NRT (Pre-OTC Switch, Patient Reports) Shiffman et al (in press)

NDAC 9/25/0620 Expanding Sources of Information for Predicting OTC Behavior  Actual patterns of Rx use  Actual patterns of OTC (BTC) use ex-US  Actual patterns of use of similar OTCs  Post-marketing surveillance

NDAC 9/25/0621 Expand Sources of Influence on OTC Behavior  Label is primary source of OTC information  Expand other points of influence  In-pack materials: Print, CDs (still considered ‘labeling’)  Consumer educational materials/programs  Behavioral programs  Outreach to physicians and other influencers  Risk Management Programs  Especially important for small at-risk populations

NDAC 9/25/0622 Evaluating Supplementary Programs  Evaluation based on importance for safe OTC use  Demonstrate the drug is OTC-able with the program  Some programs can’t be implemented/evaluated before approval

More Research Is Needed e.g., How do wording, format, order of warnings affect attention, priority, & compliance? How much does assessment lead to reactivity? How best to minimize reactivity?

NDAC 9/25/0624 Advancing the Scientific Foundations of OTC Switch  Assess “State of the Science”  Analyze past switches  Review behavioral research relevant to OTC  Collect new data on key OTC issues  Develop behavioral science of OTC Switch

NDAC 9/25/0625 Questions?